Shane R Mueller1,2, Stephen Koester3,4, Jason M Glanz5,6, Edward M Gardner7, Ingrid A Binswanger5,8. 1. Institute for Health Research, Kaiser Permanente Colorado, 10065 E. Harvard Ave., Suite 300, Denver, CO, 80231, USA. Shane.Mueller@kp.org. 2. Department of Health and Behavioral Sciences, University of Colorado Denver, Denver, CO, USA. Shane.Mueller@kp.org. 3. Department of Health and Behavioral Sciences, University of Colorado Denver, Denver, CO, USA. 4. Department of Anthropology, University of Colorado Denver, Denver, CO, USA. 5. Institute for Health Research, Kaiser Permanente Colorado, 10065 E. Harvard Ave., Suite 300, Denver, CO, 80231, USA. 6. Department of Epidemiology, Colorado School of Public Health, Denver, CO, USA. 7. Denver Health and Hospital Authority, Denver, CO, USA. 8. Division of General Internal Medicine, University of Colorado School of Medicine, Denver, CO, USA.
Abstract
BACKGROUND: Over the last 2 decades, medical providers have increasingly prescribed pharmaceutical opioids for chronic non-cancer pain, while opioid overdose death rates have quadrupled. Naloxone, an opioid antagonist, can be prescribed to patients with chronic pain to reverse an opioid overdose, yet little is known about how patients perceive this emerging practice. OBJECTIVE: This study assessed the knowledge and attitudes toward naloxone prescribing among non-cancer patients prescribed opioids in primary care. DESIGN: Qualitative study design using semi-structured interviews. PARTICIPANTS: Adults (N = 24) prescribed high-dose (≥100 morphine mg equivalent daily dose) chronic opioid therapy in eight primary care internal medicine, family medicine and HIV practices in three large Colorado health systems. APPROACH: Inductive and deductive methods were used to analyze interview transcripts. KEY RESULTS: Themes emerged related to knowledge of and benefits, barriers and facilitators to naloxone in primary care. Patients reported receiving limited education about opioid medication risks from providers and limited knowledge of naloxone. When provided with a description of naloxone, patients recognized its ability to reverse overdoses. In addition to pragmatic barriers, such as medication cost, barriers to naloxone acceptance included the perception that overdose risk stems from medication misuse and that providers might infer that they were misusing their opioid medication if they accepted a naloxone prescription, prompting an opioid taper. Facilitators to the acceptance of naloxone included medical providers' using empowering, non-judgmental communication practices, framing naloxone for use in "worst case scenarios" and providing education and training about opioids and naloxone. CONCLUSIONS: While patients recognized the utility of naloxone prescribing, we identified important barriers to patient acceptance of naloxone prescribing. To improve the naloxone prescribing acceptability in primary care practice, medical providers and health systems may need to enhance patient education, employ empowering, non-judgmental communication styles and adequately frame discussions about naloxone to address patients' fears.
BACKGROUND: Over the last 2 decades, medical providers have increasingly prescribed pharmaceutical opioids for chronic non-cancer pain, while opioid overdose death rates have quadrupled. Naloxone, an opioid antagonist, can be prescribed to patients with chronic pain to reverse an opioid overdose, yet little is known about how patients perceive this emerging practice. OBJECTIVE: This study assessed the knowledge and attitudes toward naloxone prescribing among non-cancerpatients prescribed opioids in primary care. DESIGN: Qualitative study design using semi-structured interviews. PARTICIPANTS: Adults (N = 24) prescribed high-dose (≥100 morphine mg equivalent daily dose) chronic opioid therapy in eight primary care internal medicine, family medicine and HIV practices in three large Colorado health systems. APPROACH: Inductive and deductive methods were used to analyze interview transcripts. KEY RESULTS: Themes emerged related to knowledge of and benefits, barriers and facilitators to naloxone in primary care. Patients reported receiving limited education about opioid medication risks from providers and limited knowledge of naloxone. When provided with a description of naloxone, patients recognized its ability to reverse overdoses. In addition to pragmatic barriers, such as medication cost, barriers to naloxone acceptance included the perception that overdose risk stems from medication misuse and that providers might infer that they were misusing their opioid medication if they accepted a naloxone prescription, prompting an opioid taper. Facilitators to the acceptance of naloxone included medical providers' using empowering, non-judgmental communication practices, framing naloxone for use in "worst case scenarios" and providing education and training about opioids and naloxone. CONCLUSIONS: While patients recognized the utility of naloxone prescribing, we identified important barriers to patient acceptance of naloxone prescribing. To improve the naloxone prescribing acceptability in primary care practice, medical providers and health systems may need to enhance patient education, employ empowering, non-judgmental communication styles and adequately frame discussions about naloxone to address patients' fears.
Entities:
Keywords:
naloxone; opioids; overdose; primary care; qualitative research
Authors: Ingrid A Binswanger; Stephen Koester; Shane R Mueller; Edward M Gardner; Kristin Goddard; Jason M Glanz Journal: J Gen Intern Med Date: 2015-12 Impact factor: 5.128
Authors: Denise Boudreau; Michael Von Korff; Carolyn M Rutter; Kathleen Saunders; G Thomas Ray; Mark D Sullivan; Cynthia I Campbell; Joseph O Merrill; Michael J Silverberg; Caleb Banta-Green; Constance Weisner Journal: Pharmacoepidemiol Drug Saf Date: 2009-12 Impact factor: 2.890
Authors: Phillip O Coffin; Emily Behar; Christopher Rowe; Glenn-Milo Santos; Diana Coffa; Matthew Bald; Eric Vittinghoff Journal: Ann Intern Med Date: 2016-06-28 Impact factor: 25.391
Authors: Karen H Seal; Moher Downing; Alex H Kral; Shannon Singleton-Banks; Jon-Paul Hammond; Jennifer Lorvick; Dan Ciccarone; Brian R Edlin Journal: J Urban Health Date: 2003-06 Impact factor: 3.671
Authors: Jo Ann Shoup; Shane R Mueller; Ingrid A Binswanger; Anna V Williams; John Strang; Jason M Glanz Journal: Pain Med Date: 2020-10-01 Impact factor: 3.750
Authors: Ruchir N Karmali; G Thomas Ray; Andrea L Rubinstein; Stacy A Sterling; Constance M Weisner; Cynthia I Campbell Journal: Drug Alcohol Depend Date: 2020-02-20 Impact factor: 4.492
Authors: Jason M Glanz; Komal J Narwaney; Shane R Mueller; Edward M Gardner; Susan L Calcaterra; Stanley Xu; Kristin Breslin; Ingrid A Binswanger Journal: J Gen Intern Med Date: 2018-01-29 Impact factor: 5.128
Authors: Stephanie M Mathis; Nicholas Hagemeier; Kelly N Foster; Katie Baker; Robert P Pack Journal: Subst Use Misuse Date: 2019-09-17 Impact factor: 2.164
Authors: Simeon D Kimmel; Alexander Y Walley; Sara Lodi; Leah S Forman; Jane M Liebschutz; Marlene C Lira; Theresa W Kim; Carlos Del Rio; Jeffrey H Samet; Judith I Tsui Journal: AIDS Date: 2021-03-15 Impact factor: 4.632